According to filings with the U.S. Securities and Exchange Commission, Deep Blue Medical Advances is raising up to $5,650,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Deep Blue Medical Advances
Deep Blue Medical Advances is a medical technology company established in 2015, dedicated to transforming soft tissue surgery and hernia repair by developing next-generation surgical devices. The company’s primary offering, the T-Line Hernia Mesh, is designed to provide superior anchoring strength and address the high rates of hernia occurrence and recurrence by preventing mesh fixation failure. This innovative mesh, which has received FDA 510(k) clearances in 2020 and 2022, is now being utilized in surgical suites across the US and aims to significantly impact the multi-billion-dollar global hernia device market. Deep Blue Medical Advances also has a pipeline of additional products in development, including the T-Line Tissue Control Suture (TCS) for other soft tissue procedures, and has secured over $4.6 million in grants and awards, alongside private financing rounds. The company was founded by Duke plastic surgeon Howard Levinson, MD, and continues to innovate with a focus on improving patient outcomes and surgical experiences.

To learn more about Deep Blue Medical Advances, visit https://www.deepbluemedical.com/
Deep Blue Medical Advances Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=Deep%20Blue%20Medical%20Advances

Contact:
William Perry, Chief Executive Officer
408-242-9323

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.